Acute Effects of 2C-E in Humans: An Observational Study
Por:
Papaseit, E, Olesti, E, Perez-Mana, C, Torrens, M, Grifell, M, Ventura, M, Pozo, OJ, Perna, EBDF, Ramaekers, JG, de la Torre, R and Farre, M
Publicada:
18 mar 2020
Ahead of Print:
18 mar 2020
Resumen:
2,5-Dimethoxy-4-ethylphenethylamine (2C-E) is psychedelic phenylethylamine, with a chemical structure similar to mescaline, used as new psychoactive substance (NPS). It inhibits norepinephrine and serotonin uptake and, more relevant, acts as a partial agonist of the serotonin 2A (5-HT2A), 2B (5-HT2B), and (5-HT2C) receptors. Consumers have reported that 2C-E induces mild-moderate psychedelic effects, but its pharmacology in humans, including pharmacological effects and pharmacokinetics, have not yet studied. To assess the acute effects of 2C-E on physiological and subjective effects and evaluate its pharmacokinetics, an observational study was carried-out. Ten recreational users of psychedelics self-administered a single oral dose of 2C-E (6.5, 8, 10, 15, or 25 mg). Blood pressure and heart rate were evaluated at baseline, 2, 4, and 6 h post-administration. Three rating scales were administered to evaluate subjective effects: a set of Visual Analog Scales (VAS), the 49-item short form version of the Addiction Research Centre Inventory (ARCI), and the Evaluation of the Subjective Effects of Substances with Abuse Potential (VESSPA-SSE) at baseline, 2, 4, and 6 h after self-administration. To assess 2C-E concentrations oral fluid (saliva) was collected during 6 h. 2C-E induced primarily alterations in perceptions, hallucinations, and euphoric-mood. Saliva maximal concentrations were achieved 2 h after self-administration. Administration of oral 2C-E at recreational doses produces a group of psychedelic-like effects such to 2C-B and other serotonin-acting drugs.
Filiaciones:
:
HUGTiP IGTF, Clin Pharmacol Unit, Badalona, Spain
Univ Autonoma Barcelona, Dept Pharmacol Therapeut & Toxicol, Barcelona, Spain
Univ Autonoma Barcelona, Dept Psychiat & Forens Med, Barcelona, Spain
Olesti, E:
Hosp Mar Med Res Inst IMIM, Neurosci Res Program, Integrat Pharmacol & Syst Neurosci Res Grp, Barcelona, Spain
Univ Pompeu Fabra, Dept Ciencies Experimentals & Salut CEXS UPF, Barcelona, Spain
:
HUGTiP IGTF, Clin Pharmacol Unit, Badalona, Spain
Univ Autonoma Barcelona, Dept Pharmacol Therapeut & Toxicol, Barcelona, Spain
Univ Autonoma Barcelona, Dept Psychiat & Forens Med, Barcelona, Spain
Torrens, M:
Univ Autonoma Barcelona, Dept Pharmacol Therapeut & Toxicol, Barcelona, Spain
Univ Autonoma Barcelona, Dept Psychiat & Forens Med, Barcelona, Spain
Inst Neuropsiquiatria & Adicc INAD, Drug Addict Program, Barcelona, Spain
Grifell, M:
Univ Autonoma Barcelona, Dept Pharmacol Therapeut & Toxicol, Barcelona, Spain
Univ Autonoma Barcelona, Dept Psychiat & Forens Med, Barcelona, Spain
Inst Neuropsiquiatria & Adicc INAD, Drug Addict Program, Barcelona, Spain
Assoc Benestar & Desenvolupament, Energy Control, Barcelona, Spain
Ventura, M:
Assoc Benestar & Desenvolupament, Energy Control, Barcelona, Spain
Pozo, OJ:
Hosp Mar Med Res Inst IMIM, Neurosci Res Program, Integrat Pharmacol & Syst Neurosci Res Grp, Barcelona, Spain
Perna, EBDF:
Maastricht Univ, Fac Psychol & Neurosci, Dept Neuropsychol & Psychopharmacol, Maastricht, Netherlands
Ramaekers, JG:
Maastricht Univ, Fac Psychol & Neurosci, Dept Neuropsychol & Psychopharmacol, Maastricht, Netherlands
de la Torre, R:
Hosp Mar Med Res Inst IMIM, Neurosci Res Program, Integrat Pharmacol & Syst Neurosci Res Grp, Barcelona, Spain
Univ Pompeu Fabra, Dept Ciencies Experimentals & Salut CEXS UPF, Barcelona, Spain
:
HUGTiP IGTF, Clin Pharmacol Unit, Badalona, Spain
Univ Autonoma Barcelona, Dept Pharmacol Therapeut & Toxicol, Barcelona, Spain
Univ Autonoma Barcelona, Dept Psychiat & Forens Med, Barcelona, Spain
Green Published, gold
|